 |
BioWorld-International-2002-02-27
European Academics, Industry Differ On Patent Grace Period
Oxford BioMedica Encouraged By Early Gene Therapy Studies
LONDON - Oxford BioMedica plc said it achieved positive interim results from Phase I/II trials of MetXia and TroVax, showing the two cancer gene therapy products were safe and prompted clinical improvements in several of those treated. (BioWorld International)